What are the recommended treatment options for polycythemia?

Treatment for Polycythemia Vera

All patients with polycythemia vera require therapeutic phlebotomy to maintain hematocrit below 45% and low-dose aspirin (81-100 mg daily), with cytoreductive therapy added for high-risk patients (age ≥60 years or prior thrombosis history). 1, 2

Risk Stratification

Risk stratification determines treatment intensity and directly impacts thrombosis prevention 1:

• High-risk patients: Age >60 years OR history of thrombosis 1, 2
• Low-risk patients: Age ≤60 years AND no thrombosis history 1

Universal Treatment for All Patients

Phlebotomy

• Target hematocrit: <45% in both men and women 1, 2
• The CYTO-PV study demonstrated zero thrombotic events in 66 women maintaining hematocrit <45% compared to 9 events in 72 women with hematocrit 45-50% 1
• Consider individualized lower targets (e.g., 42% for women or patients with persistent vascular symptoms) 1

Aspirin Therapy

• Dose: 81-100 mg daily 1, 2
• Contraindications include extreme thrombocytosis (platelet count ≥1000 × 10⁹/L) due to acquired von Willebrand disease and increased bleeding risk 2

Low-Risk Disease Management

Treatment consists of phlebotomy and aspirin only—cytoreductive therapy is NOT recommended as initial treatment 1:

• Maintain hematocrit <45% through therapeutic phlebotomy 1
• Aspirin 81-100 mg daily (if no contraindications) 1
• Monitor for disease progression or development of high-risk features 1

High-Risk Disease Management

First-Line Cytoreductive Therapy

Hydroxyurea is the preferred first-line cytoreductive agent 1, 3:

• Starting approach: Hydroxyurea at 2 g/day for at least 3 months 1
• Continue phlebotomy to maintain hematocrit <45% 1
• Continue aspirin 81-100 mg daily 1

Alternative First-Line Options

Interferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b should be considered for 1:

• Younger patients requiring cytoreductive therapy 1
• Pregnant patients requiring cytoreductive therapy 1

Defining Hydroxyurea Resistance or Intolerance

Hydroxyurea resistance/intolerance occurs in approximately 1 in 4 patients and is defined by any of the following criteria 1:

1. Need for phlebotomy to keep hematocrit <45% after 3 months of at least 2 g/day hydroxyurea 1
2. Uncontrolled myeloproliferation: platelet count >400 × 10⁹/L AND WBC count >10 × 10⁹/L after 3 months of at least 2 g/day hydroxyurea 1
3. Failure to reduce massive splenomegaly (>10 cm from costal margin) by >50% OR failure to completely relieve splenomegaly symptoms after 3 months of at least 2 g/day hydroxyurea 1
4. Cytopenias at lowest effective dose: absolute neutrophil count <1.0 × 10⁹/L OR platelet count <100 × 10⁹/L OR hemoglobin <10 g/dL 1
5. Unacceptable toxicities: leg ulcers, mucocutaneous manifestations, GI symptoms, pneumonitis, or fever at any dose 1

Second-Line Therapy for Hydroxyurea-Resistant or Intolerant Patients

Ruxolitinib

Ruxolitinib (JAK1/2 inhibitor) is indicated for patients resistant to or intolerant of hydroxyurea 1:

• The RESPONSE trial demonstrated that 60% of ruxolitinib-treated patients achieved hematocrit control without phlebotomy versus 20% with best available therapy 1
• Spleen volume reduction ≥35% occurred in 38% versus 1% 1
• Symptom burden reduction ≥50% occurred in 49% versus 5% 1
• Lower thrombotic event rate: 1.8% with ruxolitinib versus 8.2% with best available therapy 1
• Adverse effects: Grade 3/4 anemia (2%) and herpes zoster infection (6%) were more common 1
• 80-week follow-up showed 69% probability of maintaining complete hematologic remission 1

Alternative Second-Line Options

Interferon alfa or busulfan are second-line alternatives to ruxolitinib 3:

• Busulfan may be considered for elderly patients or those intolerant of other agents 3

Common Pitfalls

• Inadequate hematocrit control: The 45% threshold applies to both men and women despite different normal ranges; failure to maintain this target significantly increases thrombosis risk 1, 2
• Premature use of cytoreductive therapy in low-risk patients: This exposes patients to unnecessary toxicity without proven benefit 1
• Delayed recognition of hydroxyurea resistance: Use the specific criteria after 3 months at ≥2 g/day to identify candidates for second-line therapy 1
• Aspirin in extreme thrombocytosis: Withhold aspirin when platelet count ≥1000 × 10⁹/L due to acquired von Willebrand disease 2

Long-Term Outcomes

• Median survival ranges from 14.1 to 27.6 years depending on the cohort 2
• Transformation risks: 12.7% develop myelofibrosis and 6.8% develop acute myeloid leukemia 2
• Arterial thrombosis occurs in 16% and venous thrombosis in 7% at or before diagnosis 2